Merck & Co., Inc. (MRK) To Present New Clinical Data On JANUVIA® (Sitagliptin), Investigational Omarigliptin, And Real-World Data In Patients With Type 2 Diabetes At The 74th Scientific Sessions Of American Diabetes Association
6/9/2014 8:39:13 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA® (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by